Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.

Q2 Medicine
Cancer Microenvironment Pub Date : 2019-12-01 Epub Date: 2019-06-10 DOI:10.1007/s12307-019-00226-0
Mohd Rihan, Lakshmi Vineela Nalla, Anil Dharavath, Amit Shard, Kiran Kalia, Amit Khairnar
{"title":"Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.","authors":"Mohd Rihan,&nbsp;Lakshmi Vineela Nalla,&nbsp;Anil Dharavath,&nbsp;Amit Shard,&nbsp;Kiran Kalia,&nbsp;Amit Khairnar","doi":"10.1007/s12307-019-00226-0","DOIUrl":null,"url":null,"abstract":"<p><p>Metabolic reprogramming is a newly emerged hallmark of cancer attaining a recent consideration as an essential factor for the progression and endurance of cancer cells. A prime event of this altered metabolism is increased glucose uptake and discharge of lactate into the cells surrounding constructing a favorable tumor niche. Several oncogenic factors help in promoting this consequence including, pyruvate kinase M2 (PKM2) a rate-limiting enzyme of glycolysis in tumor metabolism via exhibiting its low pyruvate kinase activity and nuclear moon-lightening functions to increase the synthesis of lactate and macromolecules for tumor proliferation. Not only its role in cancer cells but also its role in the tumor microenvironment cells has to be understood for developing the small molecules against it which is lacking with the literature till date. Therefore, in this present review, the role of PKM2 with respect to various tumor niche cells will be clarified. Further, it highlights the updated list of therapeutics targeting PKM2 pre-clinically and clinically with their added limitations. This upgraded understanding of PKM2 may provide a pace for the reader in developing chemotherapeutic strategies for better clinical survival with limited resistance.</p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"12 2-3","pages":"149-167"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-019-00226-0","citationCount":"19","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12307-019-00226-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/6/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 19

Abstract

Metabolic reprogramming is a newly emerged hallmark of cancer attaining a recent consideration as an essential factor for the progression and endurance of cancer cells. A prime event of this altered metabolism is increased glucose uptake and discharge of lactate into the cells surrounding constructing a favorable tumor niche. Several oncogenic factors help in promoting this consequence including, pyruvate kinase M2 (PKM2) a rate-limiting enzyme of glycolysis in tumor metabolism via exhibiting its low pyruvate kinase activity and nuclear moon-lightening functions to increase the synthesis of lactate and macromolecules for tumor proliferation. Not only its role in cancer cells but also its role in the tumor microenvironment cells has to be understood for developing the small molecules against it which is lacking with the literature till date. Therefore, in this present review, the role of PKM2 with respect to various tumor niche cells will be clarified. Further, it highlights the updated list of therapeutics targeting PKM2 pre-clinically and clinically with their added limitations. This upgraded understanding of PKM2 may provide a pace for the reader in developing chemotherapeutic strategies for better clinical survival with limited resistance.

丙酮酸激酶M2:重新连接肿瘤微环境的代谢缺陷。
代谢重编程是癌症的一个新出现的标志,最近被认为是癌症细胞进展和耐受的重要因素。这种代谢改变的主要事件是葡萄糖摄取增加,并将乳酸释放到构建有利肿瘤生态位的细胞中。几种致癌因素有助于促进这一结果,包括丙酮酸激酶M2(PKM2),它是肿瘤代谢中糖酵解的限速酶,通过表现出其低丙酮酸激酶活性和核亮月功能来增加乳酸盐和用于肿瘤增殖的大分子的合成。它不仅在癌症细胞中的作用,而且在肿瘤微环境中的作用都必须被理解为开发针对它的小分子,这是迄今为止文献所缺乏的。因此,在本综述中,PKM2在各种肿瘤小生境细胞中的作用将得到阐明。此外,它还强调了针对PKM2的最新临床前和临床治疗方法列表及其附加的局限性。这种对PKM2的升级理解可能为读者开发化疗策略提供一个步伐,以在耐药性有限的情况下获得更好的临床生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Microenvironment
Cancer Microenvironment Medicine-Oncology
CiteScore
4.90
自引率
0.00%
发文量
0
期刊介绍: Cancer Microenvironment is the official journal of the International Cancer Microenvironment Society (ICMS). It publishes original studies in all aspects of basic, clinical and translational research devoted to the study of cancer microenvironment. It also features reports on clinical trials. Coverage in Cancer Microenvironment includes: regulation of gene expression in the cancer microenvironment; innate and adaptive immunity in the cancer microenvironment, inflammation and cancer; tumor-associated stroma and extracellular matrix, tumor-endothelium interactions (angiogenesis, extravasation), cancer stem cells, the metastatic niche, targeting the tumor microenvironment: preclinical and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信